Patent application number | Description | Published |
20090061171 | SUBSTRATES COATED WITH BRANCHED POLYURETHANES FOR ELECTROPHOTOGRAPHIC PRINTING PROCESSES - Process for printing on substrates, wherein the substrates are pre-treated with a composition which comprises a polyurethane, polyureaurethane or polyurea or a mixture thereof. | 03-05-2009 |
20090139675 | Fine-Particled Polymer Dispersions Containing Starch - Finely divided, starch-containing polymer dispersions obtainable by emulsion copolymerization, with redox initiators, of ethylenically unsaturated monomers from the group consisting of
| 06-04-2009 |
20090162624 | SUBSTRATES COATED WITH MALEIC ACID FOR ELECTROPHOTOGRAPHIC PRINTING METHOD - A process for printing on substrates, wherein the substrates are pretreated with a composition which comprises a polymer obtainable by free radical polymerization of ethylenically unsaturated compounds (monomers) (referred to below as polymer for short), and at least 1% by weight of the monomers are monomers having two carboxyl groups (dicarboxylic acid) or a dicarboxylic anhydride group (summarized below as anhydride monomer for short). | 06-25-2009 |
20090258204 | SUBSTRATES COATED WITH OLEFIN POLYMERS FOR ELECTROPHOTOGRAPHIC PRINTING METHOD - A process for printing on substrates, wherein the substrates are pretreated with a composition which comprises a polymer obtainable by free radical polymerization of ethylenically unsaturated compounds (monomers) (referred to below as polymer for short), and at least 40% by weight of the monomers are olefins. | 10-15-2009 |
20100126344 | MIXTURE COMPRISING A METAL ORGANIC FRAMEWORK AND ALSO A LATENT HEAT STORE - The present invention relates to mixtures comprising, in each case based on the total weight of the mixture,
| 05-27-2010 |
20100133280 | GAS PRESSURE VESSEL COMPRISING A MIXTURE COMPRISING A METAL ORGANIC FRAMEWORK AND ALSO A LATENT HEAT STORE - The present invention relates to a gas pressure vessel having a prescribed maximum filling pressure for the uptake, storage and release of a gas, which comprises the gas and a mixture comprising, in each case based on the total weight of the mixture,
| 06-03-2010 |
20100236736 | FINE-PARTICLED POLYMER DISPERSIONS CONTAINING STARCH - Finely divided, starch-containing polymer dispersions which are obtainable by free radical emulsion copolymerization of
| 09-23-2010 |
Patent application number | Description | Published |
20090306186 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE - There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR). | 12-10-2009 |
20140296318 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE - Methods of determining whether a patient is suitable for erythropoietin (EPO) therapy, including (A) isolating a tissue sample from said patient; (B) determining the level of expression of EPH-B4 in said sample; and (C) correlating a presence of EPH-B4 expression to a negative physiological response to EPO therapy). In addition, methods of enhancing the effectiveness of EPO therapy in a patient by administering to said patient, in conjunction with EPO therapy, an siRNA specific for EPH-B4. | 10-02-2014 |
20150081323 | SYSTEMS AND METHODS FOR DISEASE KNOWLEDGE MODELING AND CLINICAL DECISION SUPPORT - Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including drug targets and biomarkers, genes, pathways. The model is used for prioritizing treatment decisions, for treatments comprising one or more medications associated with one or more molecular entities in the model. The priority of a suggested treatment depends on at least one property of one or more medications of the suggested treatment. | 03-19-2015 |